BRAF mutation in papillary thyroid carcinoma

International Journal of Clinical and Experimental Medicine

Volumn 5, Issue 4, 2012, Pages 310-315

  Li, Xinying ^a,b   Abdel Mageed, Asim B ^a   Kandil, Emad ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

BRAF mutation; BRAF MAPK signaling pathway; Papillary thyroid carcinoma; Targeting therapy

Indexed keywords

B RAF KINASE; DEATH ASSOCIATED PROTEIN KINASE; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PENDRIN; RAS PROTEIN; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; SODIUM IODIDE SYMPORTER; SORAFENIB; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; VEMURAFENIB;

BRAF MUTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLORIMETRY; DNA SEQUENCE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; MELANOMA; MULTIPLEX POLYMERASE CHAIN REACTION; PATHOLOGY; POLYMERASE CHAIN REACTION; PYROSEQUENCING; RADIOSENSITIVITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SIGNAL TRANSDUCTION; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID CARCINOMA; THYROID NODULE; TUMOR RECURRENCE;

EID: 84866013241     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Davies L and Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-2167.
2. Leenhardt L, Grosclaude P and Cherie-Challine L. Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004; 14: 1056-1060.
3. Mazzaferri EL and Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
4. Liu D, Liu Z, Condouris S and Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 2007; 92: 2264-2271.
5. Tang KT and Lee CH. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010; 73: 113-128.
6. O'Neill CJ, Bullock M, Chou A, Sidhu SB, Delbridge LW, Robinson BG, Gill AJ, Learoyd DL, Clifton-Bligh R and Sywak MS. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 2010; 148: 1139-1145; discussion 1145-1136.
7. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM and Santoro M. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006; 12: 1623-1629.
8. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
9. Michaloglou C, Vredeveld LC, Mooi WJ and Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene 2008; 27: 877-895.
10. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ and Nikiforov YE. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005; 24: 6646-6656.
11. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M and Ringel MD. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA 2007; 104: 2803-2808.
12. Nucera C, Lawler J and Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 2011; 71: 2417-2422.
13. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V and Xing M. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006; 119: 2322-2329.
14. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A and Vigneri R. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008; 15: 191-205.
15. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D and Ladenson PW. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-6379.
16. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P and Basolo F. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 4085-4090.
17. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H and Youn YK. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 2012; 36: 310-317.
18. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ and Shong YK. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005; 63: 588-593.
19. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC and Cheng JT. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005; 63: 461-466.
20. Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE and Yip L. Both BRAF V600E mutation and older age (>/= 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 2011; 18: 3566-3571.
21. Pelttari H, Schalin-Jantti C, Arola J, Loyttyniemi E, Knuutila S and Valimaki MJ. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS 2012; 120: 380-386.
22. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S and Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840-2843.
23. Theoharis C, Roman S and Sosa JA. The molecular diagnosis and management of thyroid neoplasms. Curr Opin Oncol 2012; 24: 35-41.
24. Nikiforova MN and Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009; 19: 1351-1361.
25. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK and Frable WJ. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008; 36: 425-437.
26. Melck AL, Yip L and Carty SE. The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist 2010; 15: 1285-1293.
27. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B and Griffin A. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-470; discussion 470-461.
28. Saji M and Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 2010; 321: 20-28.
29. Montagut C and Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283: 125-134.
30. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ and Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-4719.
31. Smalley KS. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 2010; 11: 699-706.
32. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M and Salvatore G. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2010; 95: 450-455.
33. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K and Yamashita S. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006; 147: 5699-5707.
34. Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A and Giordano C. BRAFV600E mutation, TIMP-1 upregulation, and NF-kappaB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer 2011; 18: 669-685.